These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. [Which contraception for women with increased risk of venous thromboembolism?]. Julen O; Dubuisson JB; Lourenço AG Rev Med Suisse; 2011 Feb; 7(281):351-4, 356. PubMed ID: 21416714 [TBL] [Abstract][Full Text] [Related]
30. Progestin-only contraception and venous thromboembolism. Blanco-Molina MA; Lozano M; Cano A; Cristobal I; Pallardo LP; Lete I Thromb Res; 2012 May; 129(5):e257-62. PubMed ID: 22425318 [TBL] [Abstract][Full Text] [Related]
31. [Venous thromboembolism and oral contraception]. Veljković M; Popovć J Med Pregl; 2010; 63(5-6):376-9. PubMed ID: 21186550 [TBL] [Abstract][Full Text] [Related]
32. Thromboembolic events in women exposed to hormonal contraception or cyproterone acetate in 2012: a cross-sectional observational study in 30 French public hospitals. Gourbil M; Grandvuillemin A; Beyens MN; Massy N; Gras V; D'Amico A; Miremont-Salamé G; Petitpain N; Drug Saf; 2014 Apr; 37(4):269-82. PubMed ID: 24634164 [TBL] [Abstract][Full Text] [Related]
33. Combined hormonal contraception and venous thromboembolism. Martínez F; Avecilla A Eur J Contracept Reprod Health Care; 2007 Jun; 12(2):97-106. PubMed ID: 17559006 [TBL] [Abstract][Full Text] [Related]
34. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel? Meurer LN; Slawson JG J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554 [No Abstract] [Full Text] [Related]
35. The risk of thromboembolism and use of combined oral contraceptives: a comment. Birkhäuser M; Böttcher B; Germeyer A; Hadji P; Imthurn B; Mueck AO; Neulen J; Stute P; Thaler CJ; Wiegratz I; Wildt L BJOG; 2023 Jun; 130(7):844-845. PubMed ID: 36890428 [No Abstract] [Full Text] [Related]
36. [Suspension of Diane35 and its generics: an over-reaction by the French National Medicines Agency (ANSM) unfounded in the light of proven or accepted medical knowledge]. Debarre JM Ann Dermatol Venereol; 2013; 140(6-7):474-8. PubMed ID: 23773753 [No Abstract] [Full Text] [Related]
38. Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation. Pini M J Obstet Gynaecol Can; 2004 Jul; 26(7):625; author reply 626. PubMed ID: 15329967 [No Abstract] [Full Text] [Related]
39. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. Shapiro S; Dinger J J Fam Plann Reprod Health Care; 2010 Jan; 36(1):33-8. PubMed ID: 20067670 [TBL] [Abstract][Full Text] [Related]